United States Neuromodulation Market

United States Neuromodulation Market Size and Share:

The United States neuromodulation market size was valued at USD 1,908 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 3,978 Million by 2033, exhibiting a CAGR of 8.4% from 2025-2033. The market is witnessing significant growth due to the rising prevalence of chronic neurological disorders and technological advancements in neuromodulation devices. Additionally, the adoption of non-invasive neuromodulation technologies, integration of artificial intelligence and data analytics, and expanding applications in mental health treatments further contribute to market expansion.

The increasing occurrence of term disorders, such as epilepsy, Parkinson's disease, and persistent pain, represent a key driver of growth in the neuromodulation sector in the United States.   For instance, as of 2024, over 11 million people in the U.S. are living with movement disorders and approximately 3.4 million with epilepsy.   As individuals age further, these ailments  become more prevalent, thereby amplifying the demand for such solutions. All these developments, therefore, point to a very important need for innovations that will help in reducing and managing these conditions.

Technological advancements are driving the U.S. neuromodulation market as the progress in wireless communication, battery longevity, and device miniaturization have significantly enhanced the performance and usability of neuromodulation systems. For instance, in 2024, medRxiv published the first retrospective real-world analysis showing 89.2% of U.S. tinnitus patients benefited from Lenire, the only FDA-approved bimodal neuromodulation device for tinnitus treatment. In addition, closed-loop systems with patient-centric, real-time feedback have contributed to better outcomes. Approval from regulatory bodies and increases in funding for research have only hastened adoption. It all translates to fueling the expansion of the neuromodulation market across therapy types and improving patient outcomes.

United States Neuromodulation Market Trends:

Adoption of Non-Invasive Neuromodulation Technologies
 The increasing adoption of non-invasive technologies is emerging as a key trend in the US neuromodulation market. For instance, in 2024, Gray Matters Health introduced Prism for PTSD, the first self-neuromodulation device to receive FDA clearance. This groundbreaking innovation leverages advanced EEG technology and simulations to deliver personalized, non-invasive treatment for post-traumatic stress disorder (PTSD), addressing the needs of an estimated 13 million Americans affected by the condition. This development underscores the growing shift towards non-invasive solutions that combine innovation with patient-centric care, reflecting advancements in neuroscience and digital health.

Integration of Artificial Intelligence and Data Analytics
Integrating data analytics and artificial intelligence (AI) into neuromodulation devices is driving significant advancements in the field. AI-powered systems provide real-time feedback, enabling precise therapeutic adjustments based on patient-specific responses.  For instance, in 2024, Nevro launched HFX AdaptivAI, an AI-based technology that aims to deliver personalized chronic pain relief, optimizing therapy continuously even after more than 50% pain reduction.  These technologies improve precision and effectiveness, especially for conditions such as chronic diseases. Analytics data allow long-term monitoring to better treatment planning and enhanced outcomes in patients. Neuromodulation is transformed, new features are brought to the industry, and AI and analytics have revolutionized it for better patient care.

Expanding Applications in Mental Health Treatments
The most visible trend is the application of neuromodulation for managing mental health conditions, including PTSD, anxiety, and depression. For instance, in 2024, Medtronic announced FDA approval for its Percept™ RC DBS system, a cutting-edge neurostimulator designed for personalized treatment of movement disorders and epilepsy. The device boasts a 15-year battery life and advanced recharge capabilities, enhancing patient convenience. It features BrainSense™ technology, enabling clinicians to capture and record brain signals, providing data-driven insights for optimizing therapy. This innovation highlights the integration of advanced medical technology into psychiatry, addressing the growing global burden of mental health disorders with precision and adaptability.

United States Neuromodulation Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the United States neuromodulation market, along with forecasts at the country and regional levels from 2025-2033. The market has been categorized based on technology, biomaterial, and application.

Analysis by Technology:

• Internal Neuromodulation
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Vagus Nerve Stimulation (VNS)
  • Sacral Nerve Stimulation (SNS)
  • Gastric Electrical Stimulation (GES)
• External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Others
     

Internal neuromodulation refers to highly advanced implantable technologies like spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). These products ensure the delivery of accurate electrical impulses to modify the activity of nerves, thereby effectively treating diseases like chronic pain, Parkinson's disease, epilepsy, and gastrointestinal disorders. Growth in the United States neuromodulation market is being propelled by such advanced, personalized therapeutic options. Their proven efficacy and increasing adoption underscore the critical role they play in addressing complex neurological and chronic conditions.

Non-invasive external neuromodulation is treatments such as transcutaneous electrical nerve stimulation (TENS) and transcranial magnetic stimulation (TMS), which applies electrical or magnetic impulses of a specified shape and duration to the body for altering nerve activity. Already they are in wide use in the United States neuromodulation market that addresses Chronic pain, Depression, migraines, Neurological rehabilitation, etc. Their affordability, non-invasive aspect, and easy nature ensure increased availability in clinical and home settings. To meet the ever-growing demand for safe, efficient, and patient-friendly solutions in neuromodulation technologies, these innovations reinforce the market growth.

Analysis by Biomaterial:

• Metallic Biomaterials
• Polymeric Biomaterials
• Ceramic Biomaterials
   

Major contributory materials planned and used for the neuromodulation market are titanium alloys, stainless steel, or cobalt-chromium alloys owing to their superior strength, biocompatibility, and durability properties. That is part of the reason why spinal cord stimulators and deep brain stimulators can allow the device to function forever once it is safely locked in place (hands, feet, even lungs, brain). It is suitable for application in complex medical usages due to its accuracy and corrosion resistance. Metallic bio-materials increase the durability and effectiveness of the neuromodulation system which makes it enabling valuable.

The neuromodulation market in the United States is heavily reliant on polymeric biomaterials, including silicone, polyethylene, and polyetheretherketone (PEEK). They are flexible, biocompatibility, and lightweight enough to be used in the manufacture of components such as leads, electrodes, insulation systems, etc. designed for implantable devices. Their versatility enables them to be both robust and flexible, giving them the ability to function effectively within complex anatomical systems and improving patient comfort. The use of polymeric biomaterials supports the development of neuromodulation technologies, which has a clear advantage in creating safer and more efficient treatments for various conditions such as chronic pain and neurological disorders.

Neuromodulation markets in the United States are heavily reliant on ceramic biomaterials, such as alumina, zirconia, and hydroxyapatite, which exhibit high biocompatibility with other materials and have superior wear resistance. These materials are frequently employed in components of implantable neuromodulation devices, including electrode coatings and insulators. Despite their inactivity, they remain functional for an extended period and are less susceptible to degradation. Additionally, these substances are non-reactive. The U.S. healthcare industry is experiencing growth due to the use of ceramic biomaterials, which enhance patient outcomes by improving neuromodulation system reliability and performance. This progress is crucial in supporting research on neurological disorders.

Analysis by Application:

• Parkinson's Disease
• Epilepsy
• Depression
• Dystonia
• Pain Management
• Others
   

Parkinson's disease is a degenerative neurological disorder that appears through non-motor issues together with motor symptoms such as bradykinesia, stiffness, and tremors. In the US neuromodulation market, neuromodulation is a major application area, as state-of-the-art technologies like DBS offer successful symptom therapy. DBS devices enhance motor performance and help reduce medication use by producing electrical impulses in brain areas. This new treatment improves the quality of life for the patients, leading to expansion in the US healthcare market and increases in demand for neuromodulation therapies.

A significant application category in the US neuromodulation market is epilepsy, a neurological disorder characterized by recurring seizures. Advanced neuromodulation techniques including vagus nerve stimulation (VNS) and responsive neurostimulation (RNS) are effective in managing drug-resistant epilepsy. These implantable devices improve patient outcomes and reduce seizure frequency by sending precise electrical impulses to specific neural circuits. By offering effective solutions for people who are not responding to traditional treatments, neuromodulation technologies are encouraging innovation and expanding the therapeutic options available in the U.S. epilepsy treatment landscape.

One of the major application segments in the US neuromodulation market is depression, a common mental health condition marked by enduring sadness and disinterest. Neuromodulation techniques like transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS) can help patients with depression who are not responding to medication. Using electrical or magnetic impulses to alter brain function, these implantable and non-invasive devices alleviate symptoms and elevate mood. Their growing application closes gaps in mental health care, which encourages innovation and growth in the US neuromodulation industry.

An important application area in the US neuromodulation market is dystonia, a neurological movement disorder marked by involuntary muscular contractions that result in aberrant postures and motions. Deep brain stimulation (DBS) is a crucial treatment for severe, drug-resistant dystonia. By delivering precise electrical impulses to specific brain regions, DBS devices improve motor control, alleviate symptoms, and enhance patients' quality of life. Neuromodulation treatments for dystonia are becoming more popular, demonstrating their effectiveness in treating complex neurological conditions and driving advancements in the US healthcare system.

In the US neuromodulation industry, pain management is a crucial application area that treats chronic pain disorders such as complex regional pain syndrome (CRPS), neuropathic pain, and back pain. Two popular therapies, spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS), provide patients with significant relief by sending precise electrical impulses that disrupt pain signals. These therapies reduce opioid dependence by offering a substitute for chronic medication use. This is why the need for useful, less invasive pain management techniques is fueling growth in the United States neuromodulation market.

Regional Analysis:

• Northeast 
• Midwest
• South
• West
   

Such important health-care infrastructure, esteemed academic organizations, and significant research in this region of the Northeast strongly influence the US market of neuromodulation. While hospitals and clinics from throughout the country are starting to apply the latest technologies in neuromodulation in the treatment of chronic pain, epilepsy, and depression, hospitals and clinics in this corner of the world spearhead the efforts. Research institutions and medical device manufacturers collaborate to foster innovation and speed up clinical trials. The region's focus on personalized and minimally invasive therapies supports the growth and adoption of neuromodulation solutions, reinforcing its contribution to the U.S. healthcare industry.

The United States neuromodulation market has a substantial share of the Midwest region because of the strong networks of healthcare providers, established research institutions, and medical device manufacturers in the Midwest. Academic centers and hospitals across the region are leaders in neuromodulation therapies for conditions such as chronic pain, epilepsy, and movement disorders. Clinical Applications & Device Development. Key industry players encourage the development of devices and clinical applications. Furthermore, the Midwest's emphasis on increasing access to advanced treatments and pivotal clinical trials helps fuel the growth and adoption of neuromodulation technologies in the U.S. healthcare landscape.

The South region holds a very important position in the neuromodulation market of the United States. The South region is characterized by the high presence of healthcare facilities, a growing patient population, and a proactive adoption of sophisticated medical technologies. This region has a few leading hospitals and research centers working to treat chronic pain, epilepsy, and depression using neuromodulation therapies like spinal cord stimulation (SCS) and transcranial magnetic stimulation (TMS). The collaborative efforts between the educational academies and the manufacturers of medical devices promote innovation and clinical trials. However, despite being strong, this very ecosystem supports but encourages widespread adoption for neuromodulation solutions, improving patient care in this region.

The West region accounts for a significant share of the United States' neuromodulation market, driven by advanced healthcare infrastructure, a culture of innovation, and a robust presence of well-known medical device companies. This region supports cutting-edge research and development of neuromodulation technologies, such as SCS and DBS, which address chronic pain and movement disorders, among other issues. Clinical trials and specialized treatments are supported by well-known academic institutions and hospitals, but high patient demand drives adoption. While the emphasis on innovation and patient-centered care in the region is crucial, this only enhances its role in the progression of neuromodulation solutions because the need for effective treatments is increasing.

Competitive Landscape:

The United States neuromodulation market is competitive, with notable players leading the market through novel product lines and wide geographical reach through distribution networks. Even smaller firms and start-ups enter the fray, focusing their offerings on non-invasive devices and AI-based neurotechnology. Such intense competition motivates new research and product development, strategic partnerships, mergers, and acquisitions, advancing the field and increasing application areas of neuromodulation devices. For instance, in 2024, Boston Scientific acquired Axonics for $3.7 billion for sacral neuromodulation devices in its portfolio to enhance tailored neuromodulation treatments for urinary and bowel dysfunction globally and expand its high-growth urology business.

The report provides a comprehensive analysis of the competitive landscape in the United States neuromodulation market with detailed profiles of all major companies.

Latest News and Developments:

• In February 2024, Abbott and Fujirebio collaborated on the Development of Neurofilament-Light Chain Biomarker Assay for Abbott's Alinity. This is an RUO assay to support neurological research in Alzheimer's, MS, and TBI.

United States Neuromodulation Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States neuromodulation market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the United States neuromodulation market.
• Porter's Five Forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States neuromodulation industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.